Hormones and growth factors regulate cell growth via the mitogen-activated protein (MAP) kinase cascade. Here we examine the actions of the hormone somatostatin on the MAP kinase cascade through one of its two major receptor subtypes, the somatostatin receptor 1 (SSTR1) stably expressed in CHO-K1 cells. Somatostatin antagonizes the proliferative effects of fibroblast growth factor in CHO-SSTR1 cells via the SSTR1 receptor. However, in these cells, somatostatin robustly activates MAP kinase (also called extracellular signal regulated kinase; ERK) and augments fibroblast growth factor-stimulated ERK activity. We show that the activation of ERK via SSTR1 is pertussis toxin sensitive and requires the small G protein Ras, phosphatidylinositol 3-kinase, the serine/ threonine kinase Raf-1, and the protein tyrosine phosphatase SHP-2. The activation of ERK by SSTR1 increased the expression of the cyclin-dependent protein kinase inhibitor p21 cip1/WAF1
INTRODUCTION
Somatostatin is a circulating peptide hormone that displays a range of biological actions including inhibition of hormone secretion, modulation of neuronal transmission, and regulation of cell growth (1) . Somatostatin acts through a family of related G proteincoupled receptors that are variably expressed in a wide variety of tissues and tumors (2) , including the central and peripheral nervous system, the endocrine system, and the gut (3) . Upon activation of these receptors, somatostatin exerts well characterized growth-inhibitory effects in a wide variety of epithelial (4-7) and endocrine cells (8) .
Somatostatin binds to and activates at least five distinct receptor subtypes that are expressed in overlapping tissue distributions within many tissues (9, 10) . The molecular subtypes of the somatostatin receptor are organized pharmacologically into at least two groups that are distinguished both by their coupling to distinct effector pathways and by their ability to bind to distinct cyclic somatostatin analogs (11) (12) (13) (14) . While somatostatin receptor (SSTR)1 and 4 are insensitive to the cyclic somatostatin analogs, octreotide, lanreotide, and RC160, these compounds are the best known ligands for SSTR2, 3, and 5 (3, 12, 15) .
Somatostatin directly antagonizes the mitogenic action of epidermal growth factor in pancreatic tumor cells (16) and antagonizes additional tyrosine kinases in other cell types (17, 18) . This antagonism of tyrosine kinase-signaling pathways is thought to be a consequence of the ability of somatostatin to stimulate a phosphotyrosine phosphatase (PTP) activity in responsive cells (1, 7, (19) (20) (21) (22) . Many of the studies of the antiproliferative actions of somatostatin have been fo-cused on SSTR2, principally because most of the clinical experience with somatostatin involves the somatostatin agonist octreotide (23), which is a well known ligand for SSTR2, but not SSTR1 (15) . SSTR1, like SSTR2, is widely expressed in human tissues and tumors (23). Both SSTR1 and SSTR2 inhibit adenylyl cyclase when expressed in heterologous CHO-K1 cells (24) . In these cells, only SSTR1 couples to PTP activity (25). However, somatostatin can couple to PTP activity in other cell types via SSTR2 (19, 26, 27) . Recently, it has been shown that hormones as well as growth factors can regulate cell growth via their actions on the mitogen-activated protein (MAP) kinase cascade (28) (29) (30) . In this study, we examine the ability of SSTR1 to activate intracellular signaling pathways that converge on the MAP kinase cascade.
RESULTS

Somatostatin Inhibits Proliferation Stimulated by Serum and Basic Fibroblast Growth Factor (FGF) in CHO Cells Stably Expressing SSTR1
Basic FGF activates proliferation in Chinese Hamster Ovary cells (CHO-K1). To examine somatostatin's effects on FGF signaling in CHO cells, we used CHO-K1 cells that stably express somatostatin receptor SSTR1 (B max ϭ 1664 fmol/mg) (1, 24) . These cells have been extensively characterized and used as model systems for the study of somatostatin signaling via SSTR1 receptor (1, 24, 31) . The cell line used in this and prior studies (1, 24 , 31) expresses comparable levels of recombinant receptors and responds to the physiological somatostatin agonist, somatostatin-14 (SS-14), via pertussis toxin (PTX)-sensitive pathways to inhibit adenylyl cyclase with pharmacological features identical to native receptors (1, 24, 31) . Initial studies demonstrate that SS-14 significantly reduced the rate of proliferation stimulated by serum in this cell line (Fig.  1A) , as evidenced by a delay in serum-stimulated growth initiation. This cytostatic action of somatostatin is similar to that seen in other cell types (7, 32) .
Somatostatin Activates MAP Kinase via SSTR1
Growth factors like FGF are thought to activate proliferative pathways via activation of the MAP kinase cascade (33). SS-14 also inhibited FGF-induced proliferation in these cell lines (Fig. 1B) . This inhibition showed a dose dependence that was similar to SS-14's antiproliferative actions in other cell types (7, 19, 20) . Our studies showed that the activation of cell growth by FGF in these cells was inhibited by 73% (compared with stimulated levels) by the MAP kinase kinase (MEK) inhibitor PD98059 (34) (data not shown), suggesting that FGF-induced proliferation of CHO cells required activation of extracellular signal-regulated kinase (ERK). These results raised the possibility that somatostatin's actions on FGF-stimulated proliferation might be mediated via its actions on ERK as well. We examined the actions of SS-14 on ERK phosphorylation as well as activation. ERK phosphorylation at threonine-183 and tyrosine-185 are widely used indices of ERK activation by the ERK kinase MEK. We examined the phosphorylation of both ERK 1 (pERK1) and ERK2 (pERK2), using antibodies recognizing phosphotyrosine-185 (pTyr-185) in both pERK1 and pERK2. This antibody recognizes pERK2 with greater affinity than pERK1, but is specific for the "phospho" form in both cases (New England Biolabs, Beverly, MA). Initial experiments show that SS-14 increased the phosphorylation of both ERK1 and ERK2 in CHO-SSTR1 cells, but not in wild-type CHO (CHO-K1) cells. Maximal phosphorylation of both ERK1 and ERK2 was seen after 10 min of SS-14 incubation (Fig. 2A) .
We next examined the actions of SS-14 on ERK1 activation using in vitro kinase assays after immunoprecipitation of ERK1 from treated cell lysates. SS-14 strongly activated ERK1 in CHO-SSTR1 cells, reaching maximum levels within 10-20 min (Fig. 2B ). This is in contrast to results in SSTR2-expressing cells, obtained by our laboratory and others, where somatostatin does not activate MAP kinase (data not shown) (35, 36) .
To confirm the pattern of activation of MAP kinase by somatostatin in cells expressing endogenous receptors, we examined ERK activation in the pituitary cell line, GH 4 C 1 . These lacto-somatotrophic cells express predominantly SSTR1 receptors, but also express SSTR2 receptors (1) . Because SSTR1 represents the predominant somatostatin receptor subtype, SS-14 action should be mediated, in large part, via SSTR1 in these cells. After incubation of these cells with SS-14, the time course of ERK activation was similar to that seen in the CHO-SSTR1 cells (data not shown). In GH 4 C 1 cells, as in other cell types, the somatostatin agonist octreotide selectively stimulates SSTR2 and the related SSTR3 and SSTR5 receptors (32). After incubation of these cells with octreotide, very little activation of ERK1 was detected (data not shown). These results in GH 4 C 1 cells are consistent with those seen in CHO cells and suggest that SSTR1 is a strong activator of ERK whether expressed endogenously or in stably transfected cells.
SSTR1 Potentiates FGF Stimulation of ERK1
FGF can induce phosphorylation of ERK1 and ERK2 on Tyr-185 via endogenous receptors on wild-type CHO cells (CHO-K1). This action is faithfully reproduced in the CHO-SSTR1 cells (Fig. 3A) . As with SS-14, this phosphorylation was maximal at 10 min. The activation of ERK1 by FGF in CHO-SSTR1 cells was confirmed by immune complex kinase assay (Fig. 3B) . SS-14 augmented FGF's activation of ERK1 in CHO-SSTR1 cells. This is in contrast to results in SSTR2-expressing cells, where somatostatin inhibits growth factor activation of MAP kinase (data not shown) (35, 36) .
SSTR1 and FGF Induce the Expression of p21 cip1/WAF1
It has been proposed that high levels of ERK activation can cause growth arrest via the induction of p21 cip1/WAF1 (37) (38) (39) . To examine this possibility, we examined p21 cip1/WAF1 protein levels by Western blot Lysates were harvested and phospho-ERK (pERK) was detected by Western blotting, using pERK-specific antibodies. A representative Western blot is shown (n ϭ 3). The positions of pERK1 and pERK2 are indicated. B, CHO-SSTR1 cells were treated with SS-14 (1 M) for several time periods as indicated, and the lysates were immunoprecipitated using ERK1-specific antisera. Kinase assays were performed as described, and phosphorylated MBP was separated by SDS-PAGE. The results of a representative autoradiogram are shown with the position of MBP indicated (upper panel). Phosphorylated MBP was then quantitated by PhosphorImager analysis, and the fold stimulation over basal levels is presented as an average of three independent experiments (lower graph). SE is shown. (Fig. 4A) . The basal level of p21 cip1/WAF1 expression was not increased by SS-14 or FGF alone, but was increased when the hormone and growth factor were applied together. This synergistic action was seen more clearly after the immunofluorescent examination of p21 cip1/WAF1 protein. Strong nuclear staining of p21 cip1/WAF1 protein was detectable only with the combined treatment with SS-14 and FGF (Fig. 4B) . In lysates prepared from CHO-SSTR1 cells, the increase in the levels of p21 cip1/WAF1 protein seen after treatment with SS-14 and FGF was reduced after treatment with the MEK inhibitor PD98059 (34), suggesting that ERK activity was required for this action (Fig. 4C ).
SSTR1 Activation of ERK1 Requires Ras
To examine the requirement of specific proteins within the MAP kinase cascade in SS-14's activation of ERK1, we transiently transfected specific interfering mutants of upstream components of the MAP kinase cascade, including Ras, Raf, and MEK (mitogen and extracellular regulated kinase) into CHO-SSTR1 cells and examined their effects on somatostatin signaling. MEK K79R and Raf-301 are kinase-deficient mutants of MEK and Raf, respectively, that sequester endogenous downstream substrates (40) (41) (42) , and RasN17 interferes with endogenous Ras function by binding to specific Ras exchange proteins (43) . The expression of all three interfering mutants blocked myc-ERK activation by SS-14 (Fig. 5, A and B) , suggesting that MEK, Raf, and Ras were required for SS-14 activation of ERK.
SS-14 Activation of ERK1 Is Mediated by a PTXSensitive G Protein and a c-src-Like Tyrosine Kinase
The mechanisms by which G protein-coupled receptors activate the MAP kinase cascade are not fully understood. To evaluate the involvement of specific G proteins in the SSTR1-mediated activation of ERK, we pretreated CHO-SSTR1 cells with PTX. Like other known actions of SSTR1, the activation of ERK by SSTR1 was PTX sensitive (Fig. 6A) . SS-14's activation of ERK1 was also completely blocked by wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI3 kinase) (Fig. 6 , B and C). This activation of ERK1 was also completely blocked by LY294002, a second inhibitor of PI3 kinase that utilizes an independent mechanism of inhibition (Fig. 6B) . SS-14's activation of Lysates were harvested and pERK detected by Western blotting, using pERK antibodies. A representative Western blot is shown (n ϩ 3). The positions of pERK1 and pERK2 are indicated. Cells were treated with SS-14 (1 M) and FGF for 10 min, and lysates were immunoprecipitated using ERK1 antisera. Kinase assays were performed as described, and phosphorylated MBP was separated by 12% SDS-PAGE. B, The results of two representative autoradiograms and the position of MBP are shown (upper panel). Phosphorylated MBP was quantitated by PhosphorImager analysis, and the ERK1 activity is reported as fold stimulation over basal levels and presented as an average of four independent experiments (lower graph). SE is shown. ERK1 was partially blocked by herbimycin A, an inhibitor of cytoplasmic tyrosine kinases of the c-src family (Fig. 6C ). The action of these agents on FGF signaling was also examined. Herbimycin A nearly completely inhibited FGF's activation of ERK1, while wortmannin only partially reduced FGF's effect (Fig. 6C ), suggesting that while PI3 kinase was not absolutely necessary for FGF's activation of ERKs, it was necessary for that of somatostatin.
The involvement of specific G proteins in the SS-14 effects was further demonstrated by the transfection of the carboxyl-terminal domain of the ␤-adrenergic receptor kinase (␤ARKct) into CHO-SSTR1 cells. Because ␤ARKct can specifically bind to ␤␥-subunits, it has been used to demonstrate the involvement of the ␤␥-subunits in other G protein-coupled pathways (44) . The expression of ␤ARKct blocked myc-ERK activation by SS-14, confirming the involvement of the G protein ␤␥-subunits in the SSTR1 signaling to the MAP kinase cascade (Fig. 7, A and B) . A role for src-like CHO-SSTR1 cells were transfected with cDNAs encoding RasN17, Raf-301, or MEK K97R along with myc-ERK2, and cells were treated with (ϩ) or without (Ϫ) SS-14 as indicated. Cells were lysed and immune complex kinase assays were performed on cell lysates after immunoprecipitation with antimyc antibodies, using MBP as a substrate, and phosphorylated MBP was separated by 12% SDS-PAGE. A, A representative autoradiogram showing phosphorylated MBP is presented. B, Phosphorylated MBP was quantitated by PhosphorImager analysis and the fold stimulation over basal levels is presented as an average of four independent experiments. kinases in somatostatin signaling was examined after transfection of the cDNA encoding the c-src kinase (CSK). CSK phosphorylates c-src at inhibitory sites and is the major physiological inactivator of these kinases (45) . The expression of CSK blocked SS-14 activation of myc-ERK (Fig. 7, A and B) , suggesting that a cytoplasmic kinase of the src family was required for maximal activation of ERK by somatostatin.
SSTR1 Is Coupled to Raf-1 Activation
Ras-dependent activation of ERK requires members of the Raf family of serine/threonine kinases (46, 47) . Here, we examined the effects of SS-14 on Raf-1 activity, the major Raf isoform expressed in CHO cells (data not shown). SS-14 induced a significant activation of Raf-1 with a time course that mirrored ERK activation (Fig. 8, A and B) . Moreover, herbimycin A inhibited SS-14 activation of Raf-1 in these cells (Fig.  8C) , suggesting that the activation of a tyrosine kinase was required to stimulate Raf-1 as well as ERK. This is consistent with the results of other laboratories that suggest that src-like kinases are required for full activation of Raf-1 by Ras-dependent signals (47, 48) .
SSTR1 Stimulates the Activity of SH-PTP2 (SHP-2)
Somatostatin's growth effects are associated with the stimulation of a specific PTP activity (16, 22) . Previous reports have suggested that this PTP might be a member of a small family of PTPs that contain src-homology (SH2) domains, including SHP-1 (SHPTP-1, syp, PTP1D) and SHP-2 (SHPTP-2, syp, PTP1C). Src homology 2 (SH2) domains mediate protein/protein interaction via their association with specific phosphotyrosine residues. SHP-1 is expressed primarily in hematopoietic cells (49) but was not detected in CHO-SSTR1 or CHO-SSTR2 cells (Fig. 9A) . SHP-2 is widely expressed in many cell types (49), including both CHO-SSTR1 and CHO-SSTR2 cells (Fig. 9A) . To determine whether somatostatin can stimulate SHP-2 activity in CHO-SSTR1 cells, we treated these cells with SS-14 and measured PTP activity after immunoprecipitation with an antisera directed against SHP-2, in an immune complex assay using p-nitrophenylphosphate (pNPP) as a substrate. pNPP has been -2) . B, Time course of SHP-2 activity after somatostatin treatment. SHP-2 activity was measured after immunoprecipitation with anti-SHP-2 antibodies from 100 g of total cell lysate. Phosphatase activity was evaluated using the synthetic substrate pNPP using a spectrophotometric assay and is reported as the percent of basal activity. C, Coimmunoprecipitation of SHP-2 and c-src in CHO-SSTR1 cells. Cells were transfected with either control vector (pCDNA3), myc-tagged SHP-2 (SHP-2 wt), or myc-tagged SHP-2(CS) [SHP-2(CS)] and either treated for 5 min with SS-14 (ϩ) or left untreated (Ϫ). Cell lysates were immunoprecipitated with csrc antibody and Western blotted with myc antibody. The retarded migration of SHP-2 and SHP-2(CS) proteins compared with that seen in Fig. 9A is due to the increased size of the myc-tagged (Fig. 9C ) compared with endogenous SHP-2 protein (Fig. 9A) . The position of the IgG heavy chain is indicated. previously reported to be a good substrate for SHP-2 (50). The results demonstrate that SS-14 can rapidly stimulate SHP-2 activity within 1 min, reaching a maximum at 10 min, and returning to basal levels after longer treatments (Fig. 9B) .
SHP-2 Coprecipitates with c-src in Both SS-14-Treated and Untreated Cells
The involvement of src family kinases and SHP-2 in somatostatin signaling suggests the possibility that c-src or related kinases and SHP-2 may both participate within the same signaling complex. To test this hypothesis, we examined the interaction of c-src with SHP-2 in CHO-SSTR1 cells by coimmunoprecipitation. We transfected myc-tagged SHP-2 (myc-SHP-2) and myc-SHP-2(CS) into CHO-SSTR1 cells and examined whether they could associate with endogenous c-src. SHP-2(CS) encodes a catalytically inactive protein where the essential cysteine has been replaced by a serine. This mutant phosphatase binds tightly to physiological substrates without dephosphorylating them, thereby interfering with access of these substrates to endogenous wild-type SHP-2. Endogenous c-src protein was immunoprecipitated using csrc antibodies and assayed for the presence of SHP-2(CS) within the immunoprecipitates by Western blot using myc antibodies (Fig. 9C) . The results demonstrate that both SHP-2 and SHP-2(CS) can bind c-src in these cells and raise the possibility that c-src is a direct substrate of SHP-2 in these cells, as has been suggested for SHP-1 (51, 52) . The association of SHP-2 was not modulated by SS-14 treatment (Fig.  9C) , suggesting that the two proteins may be constitutively associated under basal conditions.
Maximal Activation of Raf-1 and ERK by SSTR1 Requires SHP-2
To determine whether the activation of SHP-2 was required for SSTR1 signaling to ERK, we used the interfering mutant SHP-2(CS). The interference with endogenous SHP-2 after the expression of SHP-2(CS) is specific and does not interfere with the actions of the closely related PTP, SHP-1 (53) . The expression of SHP-2(CS) in CHO-SSTR1 cells blocked SS-14's activation of both Raf-1 (Fig. 10A ) and myc-ERK (Fig. 10 , B and C), suggesting that SHP-2 was necessary for maximal activation of the MAP kinase cascade by somatostatin in these cells. In contrast, overexpression of wild-type SHP-2 did not inhibit SS-14's activation of Raf-1 (Fig. 10A) or ERK (Fig. 10, B and C) . Similar results were obtained after measurement of the transcriptional activity of Elk-1, a direct target of ERK kinase activity (54) . Using a transcription-coupled luciferase assay that reflects MAP kinase activity (55, 56) , we showed a complete inhibition of SS-14-induced Elk-1 activity after expression of SHP-2(CS) and a modest potentiation of SS-14-induced Elk-1 activity after the expression of wild-type SHP-2 (Fig.  10D) . These studies strongly suggest that endogenous SHP-2 may provide a positive signal from SSTR1 to the MAP kinase cascade.
DISCUSSION
In many cell types, the growth-promoting actions of extracellular growth factors and hormones are thought to require the activation of MAP kinase (28-30). However, in some cells, differentiation and the accompanying growth inhibition are also associated with MAP kinase activation (33, 57). For example, the expression of markers of differentiation in pituitary somatotrophs (58) and in pituitary gonadotrophs (56) requires activation of the MAP kinase cascade, as does the neuronal differentiation of cultured adrenal medullary PC12 cells (33, 41) . In this study, we examined the ability of somatostatin to activate the MAP kinase cascade via SSTR1. We and others have used stably transfected cell lines to study the biochemical action of the somatostatin receptor subtype SSTR1 (1, 19) . In any study utilizing transfected cell lines, the possibility that clonal variations arising during the selection process may influence the interpretation of the results. In this study, we utilize a well characterized SSTR1-expressing cell line (1, 24) that we have previously shown express these receptors at physiological levels and functionally couple to relevant somatostatin-signaling pathways (24). Previous studies have demonstrated that somatostatin activation of a PTPase activity accounts, in part, for its antiproliferative effects (1, 22, 25) . Because activation of PTPase activity by somatostatin has been demonstrated in CHO-SSTR1 cells (1), we have used these cells to study the regulation of proliferation and MAP kinase signaling in these cells. In the absence of additional growth factor stimulation, somatostatin activated ERK1 robustly and augmented FGF's activation of ERK1. Thus, despite inhibiting FGF-induced cellular proliferation in FGF-treated CHO-SSTR1 cells, SS-14 potentiates FGF's activation of ERKs.
The induction of growth arrest in the face of increased stimulation of MAP kinase appears to be an unlikely mechanism for growth control. However, recent studies have demonstrated that the induction of high levels of ERK activation leads to cell cycle arrest via the induction of the cell cycle inhibitor, p21 cip1/WAF1 (37) (38) (39) . p21 cip1/WAF1 is a member of a growing family of inhibitors of cyclin-dependent protein kinases (37) and is associated with the growth arrest induced by sustained activation of ERK in endocrine cells (59) . It is possible that the antiproliferative actions of SSTR1 are, in part, triggered by its stimulation of ERK activity to levels higher than that achieved by FGF alone. This is suggested by the synergistic actions of SS-14 and FGF on p21 cip1/WAF1 and the requirement of MEK for this action (Fig. 4) ; however, other mechanisms may also contribute (60) .
We show here that somatostatin's actions on MAP kinase via SSTR1 were PTX sensitive and required the activity of the ␤␥-subunits of the G proteins, like other hormones that are known to be coupled to the G i and G o subfamily of receptors [including ␣ 2A adrenergic receptors (61) and M2 muscarinic receptors (44)]. The role of ␤␥-subunits in SSTR1 signaling to MAP kinase was demonstrated here by the ability of the ␤ARKct cDNA to block SS-14's activation of MAP kinase in CHO-SSTR1 cells. ␤ARKct acts as an interfering mutant of ␤␥ signaling via the overexpression of the plekstrin homology (PH) domain of ␤ARK that functions within the full-length ␤ARK protein to permit the association of ␤ARK to ␤␥, and has been widely used to demonstrate the requirement of ␤␥ in other signaling cascades (62, 63) . ␤␥-subunits have previously been implicated in other actions of somatostatin through SSTR1, including the activation of GIRK potassium channels (64) , and the data presented here suggest that ␤␥ is required for somatostatin's activation of MAP kinase, as well.
Somatostatin's activation of ERK in CHO-SSTR1 cells was dependent on the activation of MEK, the MAP kinase kinase kinase, Raf-1, and the small G protein Ras. In addition, this action of somatostatin was blocked by wortmannin and LY294002, suggesting the involvement of PI3 kinase. These results are similar to those identified for other G i -coupled receptors, including the stimulations of MAP kinase via SSTR4 (65), serotonin 1A (66) , and the lysophosphatidic acid receptor (67) (68) (69) (70) . The activation of PI3 kinase by G protein ␤␥-subunits has also been reported (63) . PI3 kinase may be required for activation of MAP kinase by multiple hormones including somatostatin, as well as certain growth factors (71) .
We have previously reported somatostatin coupling to PTP activity in CHO-SSTR1 cells (1) . This stimulation of PTP activity in CHO-SSTR1 cells by somatostatin was G protein coupled and PTX sensitive, and correlated with somatostatin's growth effects (Fig. 1A) (1). Studies by other laboratories have suggested that the PTP stimulated by somatostatin might be an intrinsic membrane protein capable of associating with the somatostatin receptor/G protein complex (1, 25, (72) (73) (74) (75) . Here we report that SS-14 stimulation of SSTR1 increases SHP-2 activity and interfering mutants of SHP-2 activity block SS-14 activation of the MAP kinase cascade. In other cells, SHP-2 has been shown to be recruited to the plasma membranes upon somatostatin stimulation (27). A related phosphatase, SHP-1, has been implicated in somatostatin signaling (73, 75) . However, SHP-1 is principally expressed in hematopoeitic cells (76) and is not expressed in CHO-SSTR1 cells.
The time course of SHP-2 activation by somatostatin in CHO-SSTR1 cells is consistent with data from recent studies using Ras-transformed NIH3T3 after transient transfection of somatostatin receptors (26) and CHO cells stably expressing somatostatin receptors (73) . The studies presented here differ from those of Reardon and co-workers (26) who showed that SSTR2, 3, and 4, but not SSTR1 or SSTR5, could activate PTP activity when transiently expressed in v-Ras-transformed NIH 3T3 cells. In those cells, the activation of PTP was blocked by SHP-2(CS), suggesting that SHP-2 was involved. Their inability to detect coupling of SSTR1 to PTP activation in those studies may reflect the inability of transiently expressed SSTR1 to couple efficiently to downstream effectors. However, it may also point to differences in the mechanisms by which distinct somatostatin receptors couple to SHP-2. The pathway described here for SSTR1 differs from that identified for SSTR2 and SSTR3 (26) in that SSTR1 in CHO-SSTR1 cells appears to couple to cytoplasmic tyrosine kinases and utilizes G ␤␥ rather than G ␣i/o (77) . It is possible that SSTR1 utilizes a signaling pathway in whole cells that is distinct from the membrane-delimited pathways identified by others in vitro (26).
The MAP kinase kinase kinase, Raf-1, is recruited to the membrane after Ras activation and represents the last membrane-delimited protein in the growth factor/ MAP kinase cascade. Its activation by Ras is greatly potentiated by the actions of c-src (38, 48) and srcfamily tyrosine kinases (47) via two tyrosine phosphorylation sites within the Raf-1 protein at amino acids 340 and 341 (78) . The induction of PTP activity by somatostatin has been shown to dephosphorylate this site in vitro, resulting in decreased Raf-1 activity in vitro (74, 79) . We show here that somatostatin can activate both ERK and Raf-1 via SSTR1 in vivo and can augment the activation of ERK by FGF. Both the activations of ERK and Raf-1 by SS-14 can be blocked by the interfering mutant SHP-2(CS), suggesting that, at least for SSTR1, SHP-2 may be required for maximal activation of ERK. These studies suggest a role for SHP-2 in the activation of components of the MAP kinase cascade including Raf-1 and ERK.
This requirement of SHP-2 for somatostatin's activation of Raf-1 and ERK may be similar to the role of SHP-2 in signaling via many growth factors, where the activation of ERK requires the phosphatase activity of SHP-2 (80) (81) (82) (83) (84) . These studies suggest that SHP-2 may function both as adaptors, via their SH2 domains, and as enzymes that stimulate signaling to ERKs. In PC12 cells, SHP-2 and not SHP-1 is required for sustained ERK activation by FGF (53, 85) . In these cells, prolonged ERK activation is required for cessation of cell growth and neuronal differentiation and is accompanied by an induction of p21 cip1/WAF1 (59) . We show here that somatostatin also requires SHP-2 for the activation of ERKs via SSTR1, and this activation of ERKs by somatostatin is associated with cessation of cell growth and the induction of p21 cip1/WAF1 in growth factor-treated cells.
We show that SHP-2 is required for full activation of Raf-1 by somatostatin. One potential target of SHP-2 is c-src, a cytoplasmic tyrosine kinase that is physically associated with SHP-2 in CHO-SSTR1 cells and in other cell types (86) . Dephosphorylation of c-src at a single phosphotyrosine (tyrosine 529 in the mouse) is required for full activity (87, 88) and, in lymphocytes, is accomplished by the related phosphatase, SHP-1 (52, 89) . The involvement of c-src in the activation of ERKs by SS-14 in CHO-SSTR1 cells is further supported by the ability of both herbimycin A and CSK to block ERK activation via SSTR1 (Fig. 11) . However, we have not completely ruled out the role of other herbimycin Aand CSK-sensitive kinases in ERK activation, nor have we ruled out the possibility that SHP-2 may be acting on additional proteins.
In conclusion, we propose that the activation of SSTR1 is coupled positively to the MAP kinase cascade. Somatostatin's ability to potentiate growth factor stimulation of the MAP kinase cascade via SSTR1 may limit proliferative signals generated by growth factor receptors by increasing the expression of proteins like p21 cip1/WAF1 that inhibit cell cycle progression in these cells (37) .
MATERIALS AND METHODS
Materials
PTX and basic FGF were purchased from Sigma Chemical Co. (St. Louis, MO). Octreotide was provided by Sandoz Pharmaceuticals (Basel, Switzerland). Somatostatin-14 (SS-14) was purchase from American Peptides (Sunnyvale, CA). The plasma membrane is depicted by parallel dotted lines, with SSTR1 drawn as a heptahelical transmembrane protein.
At this time, neither can we propose a specific mechanism by which PI3 kinase (PI3 K) cooperates with SHP-2, nor can we rule out the possibility that c-src may be acting at additional sites upstream of Raf-1.
Herbimycin A, wortmannin, and LY294002 were purchased from CalBiochem (La Jolla, CA). Antisera directed toward ERK1, ERK2, Raf-1, SHP-1, and myc antibody 9E10 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antisera directed toward p21 cip1/WAF1 was purchased from Pharmingen (San Diego, CA) and used at 1:1000. Antibodies directed to SHP-2 and c-src were purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Antibodies directed to phospho-ERK (pThe-183,pTyr-185) were purchased from New England Biolabs, Inc. (Beverly, MA.). Radioisotopes were from NEN-DuPont (Boston, MA). All other reagents were from Sigma.
Cell Culture and Treatments
CHO-SSTR1 and GH 4 C 1 cells were maintained as previously described (1) . Before immune complex, luciferase, and immunofluorescence assays, the cells were deprived of serum and maintained in DMEM for 16 h at 37 C in 5% CO 2 before treatment with SS-14 at 1 M, for 10 min unless otherwise indicated. Basic FGF was used at 50 ng/ml. For studies examining FGF's activation of ERKs, cells were lysed after 10 min of FGF treatment. Herbimycin A was used at 1 M concentration, wortmannin was used at 100 nM to 1 M, and LY294002 was used at 25 nM. All compounds were added 10 min before SS-14 or FGF.
Proliferation Assay
Cell number was determined through the assay of mitochondrial function, using 3(4, 5-dimethythiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) as a substrate. MTT is reduced by mitochondrial dehydrogenases to form an insoluble purple precipitate that can be solublized with dimethylsulfoxide and absorbance at 570 nm quantitated as an index of cell number.
Plasmids and Transfection
The plasmids encoding RasN17, MEK K97R, Raf301, myc-ERK2, and Elk-1/Gal-4, 5xGal4-E1b/luciferase have been previously described (41) . The plasmids encoding myc-SH-PTP2 and myc-SH-PTP2(CS) were kindly provided by Dr. J. Pessin (University of Iowa, Iowa City, IA). The plasmid encoding CSK was provided by Dr. K. Rodland (Oregon Health Sciences University). The plasmid encoding myc-Raf-1 was provided by Dr. A. Shaw (Washington University, St. Louis, MO). All cell lines were grown to 50% confluence before transfection. Transfections were performed using lipofectamine per the manufacturer's instructions (GIBCO-BRL). In all experiments, total DNA transfected was kept constant with addition of pcDNA3 vector (Invitrogen, San Diego, CA). For luciferase assays, the plasmids 5xGal4-E1b/luciferase and Gal4-Elk1 were used in combination with other plasmids as indicated (41, 51, 52, 55) . For all experiments, cells were allowed to recover for 24-36 h and serum starved for 6-12 h before treatment. The C-terminal fragment of ␤ARKct was cloned by PCR from a rat brain cDNA library using specific primers to the published ␤ARK sequence (sense oligo, ATA-GAATTCGCCGCCACCATGGGAATCAAGTTACTGGAC; antisense oligo, ATATCTAGAGAATCAGAGGCCGTTGGCAC-TGCCACGCTG) and subcloned into pcDNA3. To facilitate translation, the sense oligo included a ribosomal binding cassette and a ATG start codon.
Luciferase Assay
Luciferase assays were carried out as described (41, 51, 52, 55) . Cells were transfected with 5xGal4-E1b/luciferase and Gal4-Elk1 as described and treated with somatostatin (SS-14) (1 M) or left untreated. After 6 h of treatment, cell lysates were prepared and luciferase activity was assayed as described (55) . Luciferase activity was reported as fold increase above basal levels determined from untreated serum-starved cells.
Phosphatase Assay
Cells were grown to 50% confluency, serum starved, and treated with SS-14 (1 M). At the indicated times, the cells were washed twice in PBS and lysed in a buffer containing 50 mM Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1% NP40, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, and 10 g/ml aprotinin. Total proteins (100 g) were immunoprecipitated in the same buffer using 3 g of anti-SHP-2 antibody for 4 h at 4 C. The immunoprecipitate was resuspended in 15 l of 50% protein G sepharose (Pharmacia, Piscataway, NJ) in 10 mM Tris. The entire immunoprecipitate was washed and resuspended in 100 l containing 20 l 5ϫ phosphatase buffer (25 mM EDTA, 250 mM HEPES, pH 7.2, 50 mM dithiothreitol) in the presence of the serine/threonine phosphatase inhibitor microcystin ML-R (20 nM) and ZnCl 2 (10 M), and the reaction was initiated by the addition of p-Npp substrate (10 mM, final concentration) at 30 C and incubated for 30 min. The PTPase reaction was terminated by the addition of 0.9 ml of 0.2 N NaOH, and the absorbance of the sample was measured at 410 nm, as previously reported (22).
Immune Complex Kinase Assay
Cells were grown to 50% confluence, serum-starved for 16 h, and treated with the specific agents for defined time points as indicated. Lysates were normalized for total protein, and ERK assays were performed with agarose-conjugated antisera to ERK1 (or antibodies to myc for cells transfected with myctagged ERK2) as indicated, using myelin basic protein (MBP) and [
32 P]-␥ATP as substrates (22, 41). For Raf-1 assays, untreated and treated cells were lysed in 1% NP-40 buffer containing 10 mM Tris, pH 7.4, 5 mM EDTA, 50 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride. Immune complex kinase assays were performed as described using recombinant wild-type MEK-1 (Santa Cruz) and [
32 P]-␥-ATP as substrates (90) . The reaction products of ERK and Raf-1 assays were resolved by 12% and 10% SDS-PAGE, respectively, and were analyzed with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Immunofluorescence
CHO-SSTR1 cells were plated on two-chambered slides and treated with 1 M SS-14 for the indicated times. Cells were fixed in 4% paraformaldehyde and permeabilized with acetone at Ϫ20 C for 1 min. The cells were incubated with p21 cip1/WAF1 antisera (1:1000 dilution) in PBS-0.1% BSA and fluorescein isothiocyanate-coupled antirabbit IgG and were visualized using a Leitz DMRB microscope (Leica, Inc., Deerfield, IL).
